A Phase 4 interventional study of Senna and Polyethylene glycol 3350 in Obstructive Defecation Syndrome and Postoperative Constipation, sponsored by St. Joseph's Health, New York. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by St. Joseph's Health, New York · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 346 studies in Constipation with a site in United States — 28 open to participants now, 39 under way, 5 of them phase 3. Constipation · United States.
Among the 346 studies in Constipation with a site in United States, this one is the 71st largest by planned enrollment of the 308 interventional ones that give a count, is one of 13 that started in 2025, is one of 49 in phase 4, reaches primary completion later than 24 of the 38 other live ones, and was the 324th registered.
1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.
Browse Constipation studies →28 of the 346 studies in Constipation with a site in United States are open now. Recruiting first, the newest first:
Radicle Science · Sites in United States
Ages 21–105 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 5 more countries
Ages 18–75
Peach Perfect · Sites in United States
Ages 18–60
Ardelyx · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
346 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 88 · Phase 3 73 · Phase 4 49
First in 1996; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 254 is above the median of 75 across 889 interventional studies indexed under Constipation.
Median enrollment 73 across the 308 interventional studies, 101 across the 32 observational. Of the 281 that completed or were terminated, 136 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 346 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with St. Joseph's Health, New York as lead sponsor.
St. Joseph's Health, New York has 1 study filed under Constipation — fewer than ten, so there is no comparison to draw.
20 of the studies in Constipation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT05519683Phase 3University of MichiganHome Transcutaneous Electrical Acustimulation (TEA) | 2027-03 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
| NCT05465629ViomeViome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 346 studies in Constipation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are:
What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery
The purpose of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is superior in the setting of postoperative constipation after urogynecologic surgery. This is a randomized controlled trial with the aim of comparing PEG3350 vs senna as postoperative recommended treatment for obstructive defecation constipation. Our hypothesis is that senna decreases the proportion of women with obstructive defecation constipation compared to use of PEG3350 after urogynecologic surgery. Women 18 years of age and older undergoing surgery for pelvic organ prolapse, stress urinary incontinence or both by the Department of Urogynecology at St. Joseph's Health Hospital, will be randomized to one of two study arms: senna or PEG3350. Arm 1: Polyethylene Glycol 3350, 17g, daily, oral. Arm 2: Senna (Sennosides) 8.6mg, 2 tablets daily, oral (up to 4 tablets twice a day). Interventions would be administered after surgery on postoperative day #0 and continue for 7 days total.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Senna (Sennosides), oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days
Drug: Senna
Polyethylene Glycol 3350, oral, 17g, daily for 7 days
Drug: Polyethylene glycol 3350
Senna, oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days
Also known as: Senokot, Sennoside
Polyethylene Glycol 3350, oral, 17g, daily for 7 days
Also known as: PEG 3350, Miralax
Postoperative ODS in Patients Taking PEG3350 vs Senna
The primary outcome is to determine the proportion of patients with postoperative obstructed defecation syndrome (ODS), defined as a score of nine or greater on the ODS questionnaire, in patients taking PEG3350 vs senna in the week after urogynecologic surgery.
Time frame: From enrollment to the end of treatment at 7 days after surgery.
Patient-level and Procedure-level Characteristics associated with Postoperative ODS in Patients Taking PEG3350 vs Senna
In order to identify postoperative bowel symptoms associated with ODS, enrolled participants will complete a bowel diary for 7 days after surgery. The bowel diary will include: type of bowel movement using the validated Bristol stool scale, degree of strain and pain measured on an 11-point numerical rating scale from 0-10 (zero denoting no presence of symptom and ten denoting the most severe symptom experienced), presence of splinting with bowel movements, sensation of incomplete evacuation (measured on an 11-point numerical rating scale from 0-10), additional medications taken to assist with bowel movements, fecal urgency, fecal incontinence, narcotic medication usage as well as time to first bowel movement. ODS score will be obtained preoperatively. Participants will be asked to estimate their preoperative frequency of bowel movements. Patients will self-identify their racial background. Medical records will be reviewed to obtain patient characteristics and perioperative data.
Time frame: From enrollment to the end of treatment at 7 days after surgery.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 34 phase 4 interventional studies under Constipation, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Senna Extract